Lotus Pharmaceuticals Inc (LTUS)

[guildcrantz]

I would also say that LTUS does not just tell us what we want to hear.

1) The balance sheet is ugly.
2) Revenue will be down this year because the Beijing facility is so far off schedule that they lost GMP manufacturing certification.
3) They have delayed the development of multiple drugs because the building is over budget.

The silver lining is that these problems are consistent with a bootstrapping growth company trying to build something significant from nothing.

Bradford, is your hyperbole just sour grapes or are you looking for an entry point?

Best,